Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other 1Gastrointestinal 1

Conditions

Obesity 92Overweight 35Neoplasms 32Breast Neoplasms 23Sexual Dysfunction, Physiological 19Dyspnea 15Weight Loss 12Motor Activity 12Endometrial Neoplasms 11Polycystic Ovary Syndrome 10Mucositis 8Diabetes Mellitus, Type 2 8Diabetes Mellitus 8Obesity-Related Malignant Neoplasm 7Hypertension 7Depression 7Anxiety Disorders 7Pediatric Obesity 6Colorectal Neoplasms 6Uterine Cervical Neoplasms 5Sexual Dysfunctions, Psychological 5Obesity, Morbid 5Lung Neoplasms 5Leukemia 5Endometrial Hyperplasia 5Disease 5Constipation 5Sedentary Behavior 4Pulmonary Disease, Chronic Obstructive 4Prostatic Neoplasms 4

Interventions

isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Macroglossia × Other × 1 year × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡